Xueqin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xueqin Wang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Chuan Shi
Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China
1 shared publicationDaomin Zhu
Department of Sleep Medicine Fourth People's Hospital of Hefei Affiliated Psychological Hospital of Anhui Medical University Hefei China
1 shared publicationFeng Geng
Department of Psychiatry The Second Affiliated Hospital of Anhui Medical University Hefei China
1 shared publicationGuizhong Yao
Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China
1 shared publicationHongyu Tang
Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), Beijing, China
1 shared publicationJie Sun
Department of Pain Peking University Third Hospital Peking University Beijing China
1 shared publication
Latest Publications
- 22 July 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 623-641
Fecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trial
Objective: Chronic insomnia disorder is common and burdensome, and current treatments remain limited. We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial to determine whether a fecal microbiota transplantation (FMT)‐based treatment protocol improves sleep outcomes in adults with chronic insomnia disorder. Methods: Participants were randomly assigned 1:1 to receive short‐course antibiotic pretreatment followed by donor microbiota capsules ( n = 40) or placebo capsules without antibiotic pretreatment ( n = 40). Within each group, participants were further randomized to receive synbiotic supplementation or matched placebo for prespecified exploratory subgroup analyses. The primary outcome was polysomnography‐measured sleep efficiency (SE) at 1 month after treatment. Secondary outcomes included other polysomnographic parameters, patient‐reported sleep outcomes, and safety; microbiota analyses were exploratory. Results: Compared with placebo, the FMT‐based treatment protocol improved SE (adjusted between‐group difference, 13.9 percentage points; 95% CI 7.29–20.41; p = 0.003) and reduced wake after sleep onset. Synbiotic assignment did not suggest meaningful differences in SE. Insomnia Severity Index and Pittsburgh Sleep Quality Index scores showed sustained improvement from 2 to 6 months. Treatment was well tolerated, with mild, self‐limited adverse events and no serious adverse events. The intervention increased microbial richness and diversity and altered community structure; responders and non‐responders showed similar posttreatment β ‐diversity change but differed in baseline microbiota composition. Conclusion: In adults with chronic insomnia disorder, an FMT‐based treatment protocol incorporating antibiotic pretreatment improved objective sleep continuity and sustained subjective insomnia outcomes. Baseline microbial composition may contribute to treatment heterogeneity and merits further investigation.
- 22 July 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 623-641
Fecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trial
Objective: Chronic insomnia disorder is common and burdensome, and current treatments remain limited. We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial to determine whether a fecal microbiota transplantation (FMT)‐based treatment protocol improves sleep outcomes in adults with chronic insomnia disorder. Methods: Participants were randomly assigned 1:1 to receive short‐course antibiotic pretreatment followed by donor microbiota capsules ( n = 40) or placebo capsules without antibiotic pretreatment ( n = 40). Within each group, participants were further randomized to receive synbiotic supplementation or matched placebo for prespecified exploratory subgroup analyses. The primary outcome was polysomnography‐measured sleep efficiency (SE) at 1 month after treatment. Secondary outcomes included other polysomnographic parameters, patient‐reported sleep outcomes, and safety; microbiota analyses were exploratory. Results: Compared with placebo, the FMT‐based treatment protocol improved SE (adjusted between‐group difference, 13.9 percentage points; 95% CI 7.29–20.41; p = 0.003) and reduced wake after sleep onset. Synbiotic assignment did not suggest meaningful differences in SE. Insomnia Severity Index and Pittsburgh Sleep Quality Index scores showed sustained improvement from 2 to 6 months. Treatment was well tolerated, with mild, self‐limited adverse events and no serious adverse events. The intervention increased microbial richness and diversity and altered community structure; responders and non‐responders showed similar posttreatment β ‐diversity change but differed in baseline microbiota composition. Conclusion: In adults with chronic insomnia disorder, an FMT‐based treatment protocol incorporating antibiotic pretreatment improved objective sleep continuity and sustained subjective insomnia outcomes. Baseline microbial composition may contribute to treatment heterogeneity and merits further investigation.
- 8 December 2015
- Published by Elsevier in Schizophrenia Research
- Vol. 170 (1) , 162-167
Longitudinal informed consent competency in stable community patients with schizophrenia: A one-week training and one-year follow-up study
- 8 December 2015
- Published by Elsevier in Schizophrenia Research
- Vol. 170 (1) , 162-167
Longitudinal informed consent competency in stable community patients with schizophrenia: A one-week training and one-year follow-up study